OncoMed Pharmaceuticals Inc. (OMED)

2.63
0.29 9.90
NASDAQ : Health Technology
Prev Close 2.92
Open 2.90
Day Low/High 2.49 / 2.93
52 Wk Low/High 1.74 / 5.56
Volume 251.43K
Avg Volume 199.20K
Exchange NASDAQ
Shares Outstanding 38.26M
Market Cap 120.90M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Newman Ferrara LLP Announces Corporate Governance Investigation Of OncoMed Pharmaceuticals Inc. - OMED

Newman Ferrara LLP Announces Corporate Governance Investigation Of OncoMed Pharmaceuticals Inc. - OMED

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of OncoMed Pharmaceuticals Inc.

OncoMed Announces Chairman, President And Chief Executive Officer Paul J. Hastings To Resume Chairman Responsibilities

OncoMed Announces Chairman, President And Chief Executive Officer Paul J. Hastings To Resume Chairman Responsibilities

Office of the President continues to perform the duties of President and CEO

OncoMed Chairman And CEO, Paul Hastings, To Take Medical Leave Of Absence

OncoMed Chairman And CEO, Paul Hastings, To Take Medical Leave Of Absence

Office of the President Established to Lead Company during Medical Leave

OncoMed Doses First Patient With GITRL-Fc In Phase 1a Clinical Trial

OncoMed Doses First Patient With GITRL-Fc In Phase 1a Clinical Trial

Phase 1a Study Will Assess Novel Immuno-Oncology Therapeutic Candidate as a Single Agent in Solid Tumors

OMED: Insiders vs. Shorts

The most recent short interest data was recently released for the 05/15/2017 settlement date, and OncoMed Pharmaceuticals Inc. is one of the most shorted stocks of the Russell 3000, based on 5.29 "days to cover" versus the median component at 4.71.

Newman Ferrara LLP Announces Corporate Governance Investigation Of OncoMed Pharmaceuticals Inc.

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of OncoMed Pharmaceuticals Inc.

Biotech Movers: Horizon, OncoMed, Inovio

Biotech Movers: Horizon, OncoMed, Inovio

Horizon Pharma, OncoMed Pharmaceuticals and Inovio Pharmaceuticals were among the biotech stock movers in early trading on Monday.

OncoMed Doses First Patient With Anti-TIGIT Antibody In Phase 1 Clinical Trial

Phase 1a Study Will Assess Novel Checkpoint Inhibitor as a Single Agent in Solid Tumors

OncoMed Announces Workforce Reduction

Extends Projected Cash Runway through Q3 2019 to Focus on Clinical-Stage Programs and Immuno-Oncology Discovery and Development

Wall Street Ends Its Losing Streak As Corporate Earnings Take Focus

Wall Street Ends Its Losing Streak As Corporate Earnings Take Focus

Stocks close in positive territory Monday ahead of a big week for U.S. corporate earnings.

Closing Bell: Stocks End Higher As Corporate Earnings Take Focus

Closing Bell: Stocks End Higher As Corporate Earnings Take Focus

Stocks remained in positive territory breaking a three-day losing streak ahead of U.S. corporate earnings this week, despite mounting tension between North Korea and the U.S.

Stocks Higher Ahead of Earnings From Netflix, United Airlines

Stocks Higher Ahead of Earnings From Netflix, United Airlines

Stocks rise on Monday ahead of a big week for U.S. corporate earnings, including reports Monday from Netlfix and United Airlines.

Stocks Higher as Wall Street Focuses on Earnings and Mixed Economic Data

Stocks Higher as Wall Street Focuses on Earnings and Mixed Economic Data

Stocks rise on Monday ahead of a big week for U.S. corporate earnings and as the U.S. issues a warning to North Korea.

Biotech Movers: OncoMed, Incyte, Omeros

Biotech Movers: OncoMed, Incyte, Omeros

OncoMed Pharmaceuticals, Incyte and Omeros were among the biotech stock movers in premarket trading on Monday.

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk

OncoMed Pharmaceuticals, Geron and Akorn were among the biotech stock movers in premarket trading on Monday.

Oversold Conditions For OncoMed Pharmaceuticals (OMED)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

OncoMed Pharmaceuticals Announces Bayer Terminates Its Option To License Vantictumab Or Ipafricept

OncoMed Retains Worldwide Rights to Both Wnt Pathway Programs

OncoMed's Phase 2 Demcizumab Pancreatic Cancer Trial Misses Primary Endpoint

OncoMed Management to Host Conference Call/Webcast at 8:30 a.m. ET/5:30 a.m. PT to Review Top-line Results

TheStreet Quant Rating: E+ (Sell)